{"entity":{"id":"dren-bio","kind":"company","name":"Dren Bio","aka":["Dren Bio, Inc."],"tldr":"Dren Bio is a Californian biotech whose bispecific antibodies recruit macrophages to engulf diseased cells; DR-01 directs this against CD94 to clear the cancerous cells of T-cell and natural killer cell lymphomas.","summary":"Dren Bio develops targeted myeloid engagers, bispecific antibodies that bind a disease antigen on one arm and a phagocytic receptor on macrophages with the other, so the target cell is engulfed. DR-01, its first clinical programme, depletes CD94-expressing cytotoxic lymphocytes and is in a phase 1/2 study in large granular lymphocytic leukaemia and cytotoxic lymphomas. Its CD20-directed engager DR-0201 for autoimmune disease was licensed to Sanofi in 2025.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.drenbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["dr-01"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Foster City, California","country":"US","companyType":"biotech","website":"https://www.drenbio.com/","investors":[],"funding":[]},"route":"/companies/dren-bio/","neighbours":{"drug":[{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/"}]}}